About the Webinar
In this educational webinar, Matthew Spitzer, PhD, reviews the current body of literature focused on answering the question “where do T cells get activated after cancer immunotherapy?” He also discusses his lab’s recent contribution in Cell (Rahim, Okholm, & Jones et al. 2023), which shows that successful T cell activation can be detected via peripheral blood immune profiling and that lymph node metastases can severely impair these processes. Read Teiko’s synopsis and highlights of Rahim, Okholm, & Jones et al. here.
About the Speaker
Matt Spitzer, PhD completed his training in Immunology at Stanford University in the laboratories of Garry Nolan and Edgar Engleman. There, he developed experimental and analytical methods to model the state of the immune system using high dimensional single-cell data. At Stanford, he also developed new strategies for inducing powerful immune responses against cancer.
Matt moved to UCSF in the summer of 2016 as a UCSF Parker Fellow and a Sandler Faculty Fellow and is now an Associate Professor in the Departments of Otolaryngology-Head and Neck Surgery and Microbiology & Immunology and an investigator of the Parker Institute for Cancer Immunotherapy. Matt is the scientific cofounder of Teiko Bio.
You Might Also Like
Matt Spitzer, PhD: Understanding the immune setpoint – a new approach to cancer treatment
Matthew Spitzer, Associate Professor at UCSF and scientific cofounder of Teiko Bio, explains how understanding each patient’s individual “immune setpoint” could be the key to maximizing cancer treatment efficacy.
Peripheral blood analysis is key to developing effective cancer immunotherapies
Although most research focuses on tumor-killing immune cells at the site of the tumor, new research increasingly demonstrates the value of studying circulating immune cells in peripheral blood to identify new therapeutic targets to enhance tumor-killing immune responses. We highlight recent publications with peripheral blood biomarkers and discuss recommendations for how to incorporate peripheral blood immune profiling into your drug development pipeline.
Two peas in a pod: The complementary capabilities of single-cell RNA seq and mass cytometry
Researchers have used scRNAseq and CyTOF as complementary tools in a wide variety of published studies to provide additional breadth, depth, and coverage when analyzing cellular processes. Here are a few specific examples that illustrate the diversity and range of these approaches in a variety of biomedical research settings.